10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1

_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf

パーキンソン病治療ガイドライン2002

第86回日本感染症学会総会学術集会後抄録（I）

κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β

研修コーナー

l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l

抄録／抄録１　　　　（１）Ｖ

JSP58-program

第90回日本感染症学会学術講演会抄録（I）

本文／目次（裏白）

Ł\”ƒ-2005

2 7 ( ) µ

プログラム

日本医科大学医学会雑誌第7巻第2号

Erased_PDF.pdf

2016.

第121回関東連合産科婦人科学会総会・学術集会　プログラム・抄録

1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915

プリント

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35

NewsLetter-No2

- 1 -

- 1 - HIV cmc cmc - 2 - cmc() ( ) 5-3 - - 4 - (1) (2) (3) ( ) - 5 - 0537-73-2662 0537-35-2971 0548-63-1251 9 00 16 00-6 - - 7 - 2 3 4 5 6 1,328 1,848 2,368 2,888 3,408-8 - - 9 - - 10 - - 11 - 3-12 - (

日歯雑誌（Ｈ２２・７月号）ＨＰ用／ｐ０６‐１６　クリニカル①　田崎

ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０

φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

陦ｨ邏・2

ｔｎｂｐ５９－２１＿Ｗｅｂ：Ｐ２／ｋｙ１３２３７９５０９６１０００２９４４

日本内科学会雑誌第97巻第7号

日本内科学会雑誌第98巻第4号

日歯雑誌（Ｈ２８・８月号）別刷り／ポスターセッション　とびら

α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α

original: 2011/11/5 revised: 2012/10/30, 2013/12/ : 2 V i V t2 V o V L V H V i V i V t1 V o V H V L V t1 V t2 1 Q 1 1 Q

original: 2011/11/5 revised: 2012/10/30, 2013/12/2 1 1 1: 2 V i V t2 V o V L V H V i V i V t1 V o V H V L V t1 V t2 1 Q 1 1 Q 2 2 1 2 1 c 2013 2 2: V i Q 1 I C1 V C1 V B2 I E V E V E Q 1 Q 1 Q 2 Q 2 Q

03実習2・松井.pptx

ｓｎｋｐ－１４－２／ｋｙ３４７０８４２２０２０００１９１７５

3/4/8:9 { } { } β β β α β α β β

α β : α β β α β α, [ ] [ ] V, [ ] α α β [ ] β 3/4/8:9 3/4/8:9 { } { } β β β α β α β β [] β [] β β β β α ( ( ( ( ( ( [ ] [ ] [ β ] [ α β β ] [ α ( β β ] [ α] [ ( β β ] [] α [ β β ] ( / α α [ β β ] [ ] 3

13 5 1 217.49 19.5 19.3 1 (10) (11) (4) 2 () 1 2 3 1 () 32 1 46 6 () 4 () (17) (74) 5 6 61 ー 7 () ( ) 8 9 10 11 12 27 31 5 13 829-1844 620-2654 669-6054 646-3054 681-6054 840-6054 856-6164 829-6124 844-7164

JFC11j-kokumin_SKM-Master.indd

13 13 1634 1 22 271 144 13 118 216 1 634 3,512 8,19 (1 2 3 () 4 994 22 2 4.4% 119 8.6% 59 21.1% 4 65.9% () 1 7.4% 1 5.% 42.6% () 83 7 22 318,94 22 27.8% 77.% () 1 2 15.3% 23.% 318,94 22 76.3% () 1 2 23.7%

, TV,

日本内科学会雑誌第102巻第4号

NL10

Information September, 2006 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.10 September, 2006 3 2006 4 Japanese Association for Molecular Target Therapy of Cancer News Letter

日本医科大学医学会雑誌第8巻第1号

Xenopus laevis in situ μ μ Xenopus laevis Xenopus laevis Xenopus laevis UGT1A1 UGT1A1 IL28B KRAS UGT1A1 UGT1A128 UGT UGT1A1 UGT1A128 UGT1A1 286 UGT1A1 UGT1A1 28 6 UGT UGT UGT1A128 UGT IL28B UGT1A1

研修コーナー

l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,

1 (1) () (3) I 0 3 I I d θ = L () dt θ L L θ I d θ = L = κθ (3) dt κ T I T = π κ (4) T I κ κ κ L l a θ L r δr δl L θ ϕ ϕ = rθ (5) l

1 1 ϕ ϕ ϕ S F F = ϕ (1) S 1: F 1 1 (1) () (3) I 0 3 I I d θ = L () dt θ L L θ I d θ = L = κθ (3) dt κ T I T = π κ (4) T I κ κ κ L l a θ L r δr δl L θ ϕ ϕ = rθ (5) l : l r δr θ πrδr δf (1) (5) δf = ϕ πrδr

NL09

Information September, 2005 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.9 September, 2005 3 2005 4 Japanese Association for Molecular Target Therapy of Cancer News Letter

ｎｓｇ０４－２８／ｋｙ２０８６８４３５６１０００４３０７７

δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!

日本分子第5巻2号_15特別講演・シンポジウム.indd

25 JSMI Report JSMI Report 26 41 JSMI Report JSMI Report 42 JSMI Report 54 55 JSMI Report JSMI Report 56 57 JSMI Report JSMI Report 58 59 JSMI Report JSMI Report 60 61 JSMI Report β JSMI Report 62 63 JSMI

I II III IV V

I II III IV V N/m 2 640 980 50 200 290 440 2m 50 4m 100 100 150 200 290 390 590 150 340 4m 6m 8m 100 170 250 µ = E FRVβ β N/mm 2 N/mm 2 1.1 F c t.1 3 1 1.1 1.1 2 2 2 2 F F b F s F c F t F b F s 3 3 3

NL11

information September, 2007 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.11 September, 2007 3 2007 4 Japanese Association for Molecular Target Therapy of Cancer News Letter

untitled

2003 20032003 FTAEPA 9 1999 1 1967 1992 2,240 2001 1,000 30 3 2003 2004 1 4 10-1- 2 2 6 6.5 2 4 2 2-2- 5 *1 *2 *1 2003pp.3-7. *2 1989p.114. -3- *3 *4 *3 1997p.91. *4 2002pp.92-93. -4- 1990-5- 98 *5 *5

x 3 a (mod p) ( ). a, b, m Z a b m a b (mod m) a b m 2.2 (Z/mZ). a = {x x a (mod m)} a Z m 0, 1... m 1 Z/mZ = {0, 1... m 1} a + b = a +

1 1 22 1 x 3 (mod ) 2 2.1 ( )., b, m Z b m b (mod m) b m 2.2 (Z/mZ). = {x x (mod m)} Z m 0, 1... m 1 Z/mZ = {0, 1... m 1} + b = + b, b = b Z/mZ 1 1 Z Q R Z/Z 2.3 ( ). m {x 0, x 1,..., x m 1 } modm 2.4

感染症学雑誌第77巻第8号

1 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ

内科１０１巻３号／ｎａｉ０３‐０１（試験問題抜粋）

1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38

2007 2006 11 29 1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38 40 40 40 11 41 41 42 42 43 43 44 45 46 46 47 47 49 50 51 51 52 53

数学概論I

{a n } M >0 s.t. a n 5 M for n =1, 2,... lim n a n = α ε =1 N s.t. a n α < 1 for n > N. n > N a n 5 a n α + α < 1+ α. M := max{ a 1,..., a N, 1+ α } a n 5 M ( n) 1 α α 1+ α t a 1 a N+1 a N+2 a 2 1 a n

EPSON LP-8900ユーザーズガイド

3 4 5 6 7 8 abc ade w p s 9 10 s s 11 p 12 p 13 14 p s 15 p s A B 16 w 17 C p 18 D E F 19 p w G H 20 A B 21 C s p D 22 E s p w 23 w w s 24 p w s 25 w 26 p p 27 w p s 28 w p 29 w p s 30 p s 31 A s B 32

n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m

1 1 1 + 1 4 + + 1 n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m a n < ε 1 1. ε = 10 1 N m, n N a m a n < ε = 10 1 N

Evolutes and involutes of fronts Masatomo Takahashi Muroran Institute of Technology

Evolutes and involutes of fronts Masatomo Takahashi Muroran Institute of Technology evolute involute, evolvent involute : involvo evolvent : evolvo 6 4 6 4 4 6 4 6 H 3 γ : I R C γ(t) 0, t(t) := γ(t) γ(t),

untitled

( 9:: 3:6: (k 3 45 k F m tan 45 k 45 k F m tan S S F m tan( 6.8k tan k F m ( + k tan 373 S S + Σ Σ 3 + Σ os( sin( + Σ sin( os( + sin( os( p z ( γ z + K pzdz γ + K γ K + γ + 9 ( 9 (+ sin( sin { 9 ( } 4

MM0508-見聞記01.ind

函館市_絵で見てわかる

70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183

2 1 1 α = a + bi(a, b R) α (conjugate) α = a bi α (absolute value) α = a 2 + b 2 α (norm) N(α) = a 2 + b 2 = αα = α 2 α (spure) (trace) 1 1. a R aα =

1 1 α = a + bi(a, b R) α (conjugate) α = a bi α (absolute value) α = a + b α (norm) N(α) = a + b = αα = α α (spure) (trace) 1 1. a R aα = aα. α = α 3. α + β = α + β 4. αβ = αβ 5. β 0 6. α = α ( ) α = α

XV-Z10000(J)Ł\1-4.p65

http://www.sharp.co.jp/ 4 2-JW age 2 2..5, :42 2 age 2 2..5, :44 3 age 3 2..5, :44 4 2..5, :44 age 4 5 2..5, :44 age 5 6 2..5, :44 age 6 7 2..5, :44 age 7 8 age 8 2..5, :45 75 76 9 age 9 2..5, :45 4 4

‚æ62›ñ”©fi®”Ô‰Z‘p›ï‘Ü

日本内科学会雑誌第96巻第7号

α β *2 α α β β α = α 1 β = 1 β 2.2 α 0 β *3 2.3 * *2 *3 *4 (µ A ) (µ P ) (µ A > µ P ) 10 (µ A = µ P + 10) 15 (µ A = µ P +

Armitage 1 1.1 2 t *1 α β 1.2 µ x µ 2 2 2 α β 2.1 1 α β α ( ) β *1 t t 1 α β *2 α α β β α = α 1 β = 1 β 2.2 α 0 β 1 0 0 1 1 5 2.5 *3 2.3 *4 3 3.1 1 1 1 *2 *3 *4 (µ A ) (µ P ) (µ A > µ P ) 10 (µ A = µ P

内科９６巻３号★／ＮＡＩ３‐１（第２２回試験問題）

µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2

医系の統計入門第 2 版 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. このサンプルページの内容は, 第 2 版 1 刷発行時のものです.

医系の統計入門第 2 版 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. http://www.morikita.co.jp/books/mid/009192 このサンプルページの内容は, 第 2 版 1 刷発行時のものです. i 2 t 1. 2. 3 2 3. 6 4. 7 5. n 2 ν 6. 2 7. 2003 ii 2 2013 10 iii 1987

N cos s s cos ψ e e e e 3 3 e e 3 e 3 e

3 3 5 5 5 3 3 7 5 33 5 33 9 5 8 > e > f U f U u u > u ue u e u ue u ue u e u e u u e u u e u N cos s s cos ψ e e e e 3 3 e e 3 e 3 e 3 > A A > A E A f A A f A [ ] f A A e > > A e[ ] > f A E A < < f ; >

長崎県県央保健所事業概要

P1 P2~P3 P4 P5 P7~P10 P11~P40 P41~P174 P175~P179 P181~P212 271,417 2 3 4 5 5 7 8 9 10 12 13 14 15 16 18 19 2,506 365 293 5 20 2 4 123 4 17 1 2 143 351 5 3 18 40 10 475 3 2 22 22 66 1 13 18 31 10

( )

) ( ( ) 3 15m t / 1.9 3 m t / 0.64 3 m ( ) ( ) 3 15m 3 1.9m / t 0.64m 3 / t ) ( β1 β 2 β 3 y ( ) = αx1 X 2 X 3 ( ) ) ( ( ) 3 15m t / 1.9 3 m 3 90m t / 0.64 3 m ( ) : r : ) 30 ( 10 0.0164

2.1: n = N/V ( ) k F = ( 3π 2 N ) 1/3 = ( 3π 2 n ) 1/3 V (2.5) [ ] a = h2 2m k2 F h2 2ma (1 27 ) (1 8 ) erg, (2.6) /k B 1 11 / K

2 2.1? [ ] L 1 ε(p) = 1 ( p 2 2m x + p 2 y + pz) 2 = h2 ( k 2 2m x + ky 2 + kz) 2 n x, n y, n z (2.1) (2.2) p = hk = h 2π L (n x, n y, n z ) (2.3) n k p 1 i (ε i ε i+1 )1 1 g = 2S + 1 2 1/2 g = 2 ( p F

447号.indd

Eubalaena australis ( 2006 2,400 6.4% 1993-2008 1,2 1997 69 - - 2 2003 3,400 7.3% 1971-2003 2 1995 137 - - 2 1997 2,577 6.9% 1971-1990 2 1997 7,500 - - 2 1: IWC (2009). IWC/61/REP 1 (Annex H). 2: IWC (2009).

arxiv: v1(astro-ph.co)

arxiv:1311.0281v1(astro-ph.co) R µν 1 2 Rg µν + Λg µν = 8πG c 4 T µν Λ f(r) R f(r) Galileon φ(t) Massive Gravity etc... Action S = d 4 x g (L GG + L m ) L GG = K(φ,X) G 3 (φ,x)φ + G 4 (φ,x)r + G 4X (φ)

untitled

The 23rd Annual Meeting of the Japanese Association of Cardiac Rehabilitation! The 23rd Annual Meeting of the Japanese Association of Cardiac Rehabilitation The 23rd Annual Meeting of the Japanese Association

TEL-E7

Ni-Cd TEL-E7 TEL-EW7 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 9 20 Ni-Cd 2 3 2 2 3 22 2 2 3 4 3 4 23 2 2 3 3 24 25 2 3 4 2 3 4 26 2 3 2 3 27 2 2 2 28 2 2 2 29 2 3 2 4 30 2 2 3 3 2 3 2 3 3 32 33 2 3 34 2 3 35

O x y z O ( O ) O (O ) 3 x y z O O x v t = t = 0 ( 1 ) O t = 0 c t r = ct P (x, y, z) r 2 = x 2 + y 2 + z 2 (t, x, y, z) (ct) 2 x 2 y 2 z 2 = 0

9 O y O ( O ) O (O ) 3 y O O v t = t = 0 ( ) O t = 0 t r = t P (, y, ) r = + y + (t,, y, ) (t) y = 0 () ( )O O t (t ) y = 0 () (t) y = (t ) y = 0 (3) O O v O O v O O O y y O O v P(, y,, t) t (, y,, t )

13 6 2 68 34 JIS S0026 JIS JIS S0026 50000 2550mm 2550mm 2550mm 12 1 4 15 ( ) 3000 1 1 H17 ttp://www.isuzu.co.jp/product/bus/gala_ss/approach.html

総合薬学講座 生物統計の基礎

2013 10 22 ( ) 2013 10 22 1 / 40 p.682 1. 2. 3 2 t Mann Whitney U ). 4 χ 2. 5. 6 Dunnett Tukey. 7. 8 Kaplan Meier.. U. ( ) 2013 10 22 2 / 40 1 93 ( 20 ) 230. a t b c χ 2 d 1.0 +1.0 e, b ( ) e ( ) ( ) 2013

> > <., vs. > x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D > 0 x (2) D = 0 x (3

13 2 13.0 2 ( ) ( ) 2 13.1 ( ) ax 2 + bx + c > 0 ( a, b, c ) ( ) 275 > > 2 2 13.3 x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D >

セアラの暗号

1 Cayley-Purser 1 Sarah Flannery 16 1 [1] [1] [1]314 www.cayley-purser.ie http://cryptome.org/flannery-cp.htm [2] Cryptography: An Investigation of a New Algorithm vs. the RSA(1999 RSA 1999 9 11 2 (17

- 2 -

- 1 - RI Martin D. Kamen P450 MD Kamen Vanderbilt Howard Gest Indiana 32 P J. Biol. Chem., 1948 15N - 2 - - 3 - ATP ATP-DnaA/oriC DnaB DnaC DnaG DNA III B (pol III* + β ) G B G pol III* β - 4 - β Hda A

Microsoft Word - 【140821差し替え】日本人の食事摂取基準（2015年版）概要

1 estimated average requirement recommended dietary allowance adequate intake tolerable upper intake level tentative dietary goal for preventing life-style related diseases 2 1 n 6 n 3 A D E K B1 B2 B6

,,,,., = (),, (1) (4) :,,,, (1),. (2),, =. (3),,. (4),,,,.. (1) (3), (4).,,., () : = , ( ) : = F 1 + F 2 + F 3 + ( ) : = i Fj j=1 2

6 2 6.1 2 2, 2 5.2 R 2, 2 (R 2, B, µ)., R 2,,., 1, 2, 3,., 1, 2, 3,,. () : = 1 + 2 + 3 + (6.1.1).,,, 1 ,,,,., = (),, (1) (4) :,,,, (1),. (2),, =. (3),,. (4),,,,.. (1) (3), (4).,,., () : = 1 + 2 + 3 +,

_<74B0><5883><611F><67D3><30DD><30B1><30D7><30ED>_<5FF5><6821>2.pdf

33 The 33rd Annual Meeting of Japanese Society for Infection Prevention and Control The 33rd Annual Meeting of Japanese Society for Infection Prevention and Control The 33rd Annual Meeting of Japanese

untitled

c OR 21 OR 1. 21 21 IoT OR OR OR 260 8672 1 8 1 OR 2. 2.1 public health [1] communicable (infectious) diseases vehicle burden HIV/AIDS (SARS) 258 60 Copyright c by ORSJ. Unauthorized reproduction of this

gr09.dvi

.1, θ, ϕ d = A, t dt + B, t dtd + C, t d + D, t dθ +in θdϕ.1.1 t { = f1,t t = f,t { D, t = B, t =.1. t A, tdt e φ,t dt, C, td e λ,t d.1.3,t, t d = e φ,t dt + e λ,t d + dθ +in θdϕ.1.4 { = f1,t t = f,t {

喘息について\(公健協会宛02-5作成\)

Q & A Q & A 1.? 20 2. 1) 2) 3) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 8) 9) 3. NHK ( ) 4 10 1 200mg ( ) ( 1 ) 4. ( ) ( ) 5. ( ) ( ) 6. β 2 ( ) 7. ( ) 1 8. 1. 2. 3. 4. 5. 6. 7. 8. 9. 2 5 7 1. 1 10 1) 2) 3) 30

τ τ

1 1 1.1 1.1.1 τ τ 2 1 1.1.2 1.1 1.1 µ ν M φ ν end ξ µ ν end ψ ψ = µ + ν end φ ν = 1 2 (µφ + ν end) ξ = ν (µ + ν end ) + 1 1.1 3 6.18 a b 1.2 a b 1.1.3 1.1.3.1 f R{A f } A f 1 B R{AB f 1 } COOH A OH B 1.3

H 0 H = H 0 + V (t), V (t) = gµ B S α qb e e iωt i t Ψ(t) = [H 0 + V (t)]ψ(t) Φ(t) Ψ(t) = e ih0t Φ(t) H 0 e ih0t Φ(t) + ie ih0t t Φ(t) = [

3 3. 3.. H H = H + V (t), V (t) = gµ B α B e e iωt i t Ψ(t) = [H + V (t)]ψ(t) Φ(t) Ψ(t) = e iht Φ(t) H e iht Φ(t) + ie iht t Φ(t) = [H + V (t)]e iht Φ(t) Φ(t) i t Φ(t) = V H(t)Φ(t), V H (t) = e iht V (t)e

II ( ) (7/31) II ( [ (3.4)] Navier Stokes [ (6/29)] Navier Stokes 3 [ (6/19)] Re

II 29 7 29-7-27 ( ) (7/31) II (http://www.damp.tottori-u.ac.jp/~ooshida/edu/fluid/) [ (3.4)] Navier Stokes [ (6/29)] Navier Stokes 3 [ (6/19)] Reynolds [ (4.6), (45.8)] [ p.186] Navier Stokes I Euler Navier

<95F18D908F91967B95B62E696E6464>

1.. (1-1)? 1. 2.,,.. (1-2)? 1. 2. 3. 4. 5. 6. 7. (1-3)?. (() ().) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. (: ) (1-4). 1. 2. 3. 4. 5. 6. 7. ( ) (1-5)?. 1. 2. 3. (1-6)?. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. - 0

微分積分 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. このサンプルページの内容は, 初版 1 刷発行時のものです.

微分積分 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. ttp://www.morikita.co.jp/books/mid/00571 このサンプルページの内容は, 初版 1 刷発行時のものです. i ii 014 10 iii [note] 1 3 iv 4 5 3 6 4 x 0 sin x x 1 5 6 z = f(x, y) 1 y = f(x)

Lagrange.dvi

Lagrange 1 2006.2.10 1 Introduction CfA survey 2dF SDSS high-z Euler Lagrange Lagrange CDM Lagrange Lagrange 2 Newton Friedmann Newton Newton Newton [1,2,3,4,5] ρ + r ρu = 0, 1 t r u +u r u = 1 t r ρ rp

90 NPO NPO NPO NPO NPO NPO

89 NPO NPO NPO 90 NPO NPO NPO NPO NPO NPO 91 m 92 NPO 93 94 NPO 95 96 NPO In Japan, Buddhism May Be Dying Out Dying Out Dying Out 97 98 NPO ips 99 ISM 100 NPO NPO HIV NGO NPO HIV HIV km 101 HIV HIV HIV

CVMに基づくNi-Al合金の

CV N-A (-' by T.Koyama ennard-jones fcc α, β, γ, δ β α γ δ = or α, β. γ, δ α β γ ( αβγ w = = k k k ( αβγ w = ( αβγ ( αβγ w = w = ( αβγ w = ( αβγ w = ( αβγ w = ( αβγ w = ( αβγ w = ( βγδ w = = k k k ( αγδ

日本産科婦人科学会雑誌第64巻第12号

23 1 Section ( ) ( ) ( 46 ) , 238( 235,238 U) 232( 232 Th) 40( 40 K, % ) (Rn) (Ra). 7( 7 Be) 14( 14 C) 22( 22 Na) (1 ) (2 ) 1 µ 2 4

23 1 Section 1.1 1 ( ) ( ) ( 46 ) 2 3 235, 238( 235,238 U) 232( 232 Th) 40( 40 K, 0.0118% ) (Rn) (Ra). 7( 7 Be) 14( 14 C) 22( 22 Na) (1 ) (2 ) 1 µ 2 4 2 ( )2 4( 4 He) 12 3 16 12 56( 56 Fe) 4 56( 56 Ni)

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky

2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)

Radiation from moving charges#1 Liénard-Wiechert potential Yuji Chinone 1 Maxwell Maxwell MKS E (x, t) + B (x, t) t = 0 (1) B (x, t) = 0 (2) B (x, t)

Radiation from moving harges# Liénard-Wiehert potential Yuji Chinone Maxwell Maxwell MKS E x, t + B x, t = B x, t = B x, t E x, t = µ j x, t 3 E x, t = ε ρ x, t 4 ε µ ε µ = E B ρ j A x, t φ x, t A x, t